How to Get Tresiba (Insulin Degludec) in Montana

What Is Tresiba and Why Do Montana Patients Request It?

Tresiba is a once-daily basal insulin with a half-life of roughly 25 hours and a duration of action exceeding 42 hours, giving it a flatter, more predictable pharmacokinetic profile than insulin glargine U-100 [1]. That flat profile is the main reason endocrinologists and primary care providers prescribe it for patients who experience nocturnal hypoglycemia or highly variable fasting glucose on older basal insulins.

The landmark DEVOTE trial (N=7,637, 2-year follow-up) compared insulin degludec to insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk [2]. Degludec produced a 40% lower rate of severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48, 0.76, P<0.001) while achieving non-inferior cardiovascular outcomes (MACE hazard ratio 0.91 to 95% CI 0.78, 1.06) [2]. A companion analysis published in Diabetes Care confirmed that nocturnal severe hypoglycemia was reduced by 53% compared with glargine [3].

Montana's geography makes consistent glucose management harder for many patients. Rural residents may live 90 minutes from the nearest endocrinologist, making flexible dosing windows (Tresiba allows up to an 8-hour shift in injection time) and low hypoglycemia rates especially valuable [4]. The FDA label permits dose flexibility specifically because degludec's ultra-long half-life buffers the pharmacodynamic effect of timing variation [4].

For type 1 diabetes, a randomized trial by Mathieu et al. (N=499) published in Diabetes Care found that degludec achieved similar HbA1c reduction to glargine while reducing confirmed nocturnal hypoglycemia by 25% (rate ratio 0.75, P<0.001) [5]. The American Diabetes Association 2024 Standards of Care note that "longer-acting basal insulin analogs (degludec, glargine U-300) reduce the risk of hypoglycemia compared with NPH insulin" [6].

Who Can Prescribe Tresiba in Montana?

Any licensed Montana prescriber with Schedule II, V authority can write a Tresiba prescription. That group includes MDs, DOs, nurse practitioners (NPs) with full practice authority, and physician assistants (PAs) with a supervising-physician agreement where required.

Montana granted NPs full independent practice authority under Montana Code Annotated 37-8-202, meaning an NP can initiate, adjust, and renew insulin degludec without physician co-signature [7]. PAs in Montana prescribe under a delegation agreement with a supervising physician; that agreement typically covers all legend drugs including insulin [7]. Telehealth providers holding a Montana license or a compact license (Montana joined the Interstate Medical Licensure Compact) can prescribe after a synchronous audio-visual visit that satisfies the valid patient-provider relationship standard [8].

The Montana Board of Medical Examiners does not impose a separate telemedicine registration for prescribing schedule-exempt drugs like insulin, so a standard Montana license suffices [8]. HealthRX clinicians prescribing for Montana patients hold active Montana licensure and conduct video consultations that meet this standard.

How to Get a Tresiba Prescription via Telehealth in Montana

Telehealth prescribing of Tresiba in Montana follows a straightforward four-step path.

Step 1. Book a synchronous visit. Montana statute requires a real-time audio-visual connection for the initial prescribing encounter [8]. Asynchronous questionnaire-only visits do not satisfy the valid-relationship requirement for a new insulin prescription.

Step 2. Share recent labs. An A1C drawn within the past 90 days is the minimum. Providers also review fasting glucose logs, a recent CMP (to assess renal function, since dose adjustment guidance exists for eGFR <30 mL/min/1.73m²), and the patient's current insulin regimen [4]. The FDA label notes no specific dose adjustment is required by renal impairment alone, but clinical monitoring is advised [4].

Step 3. Receive electronic prescription. Montana law permits e-prescribing for non-controlled substances including insulin. The provider sends the prescription directly to the patient's preferred pharmacy, including mail-order pharmacies [9].

Step 4. Fulfill at pharmacy. Tresiba is stocked by most major chains (Walgreens, CVS, Walmart Pharmacy) and independent pharmacies in Montana's larger cities, including Billings, Missoula, Great Falls, and Bozeman. Mail-order fulfillment through Novo Nordisk's pharmacy partners typically ships within 2 to 5 business days to Montana ZIP codes.

The typical end-to-end timeline from telehealth visit to insulin-in-hand runs 3 to 7 days for most Montana patients when prior authorization is not required.

What Labs Are Needed Before Starting Tresiba?

Baseline laboratory evaluation before initiating insulin degludec follows the ADA 2024 Standards of Care framework for basal insulin initiation [6]. Providers typically order:

• HbA1c: Establishes glycemic baseline and informs starting dose. The ADA recommends a target of <7.0% for most non-pregnant adults [6].
• Fasting plasma glucose: Calibrates the initial dose; most titration algorithms target fasting glucose of 80 to 130 mg/dL [6].
• Comprehensive metabolic panel: Assesses renal and hepatic function. Hepatic impairment may increase insulin sensitivity, requiring dose reduction [4].
• C-peptide (for type 1 workup): A fasting C-peptide <0.6 ng/mL with concurrent glucose >200 mg/dL supports insulin deficiency [10].
• Thyroid-stimulating hormone: Thyroid dysfunction alters insulin sensitivity and is commonly assessed at diabetes initiation visits.
• Lipid panel: Required by many prior-authorization forms as part of metabolic documentation.

No specialized genetic test or imaging is required before Tresiba initiation. If transitioning from another basal insulin, the FDA label recommends a 1:1 unit conversion from insulin glargine or insulin detemir, with subsequent titration every 3 to 4 days based on fasting glucose [4].

Montana Medicaid and Insurance Coverage for Tresiba

Montana Medicaid does not cover Tresiba for either type 1 or type 2 diabetes as of the current preferred drug list. Patients enrolled in Medicaid will need either a medical exception/prior authorization demonstrating failure of a covered basal insulin (typically glargine U-100 or NPH) or a switch to a covered alternative [11].

For commercial insurance, prior authorization is standard. The documentation packet typically includes:

1. Prescriber attestation of medical necessity
2. Most recent A1C result (usually <180 days old)
3. Documented history of hypoglycemia on a formulary basal insulin (glucose logs, CGM reports, or chart notes documenting at least one severe episode qualify)
4. For type 2 patients, evidence that metformin and one other oral agent were tried when appropriate
5. Prescriber's diagnosis (type 1, type 2, or secondary diabetes) with ICD-10 code

The ADA's 2024 consensus statement on insulin access states: "Barriers to insulin access, including prior authorization delays, directly harm patient outcomes and should be minimized by payers" [6]. That language is increasingly cited in appeal letters when initial PA requests are denied.

Medicare Part D plans vary. As of 2025, the $35/month out-of-pocket cap for insulin applies to all Medicare Part D beneficiaries regardless of low-income subsidy status [12]. Tresiba appears on many Part D formularies at Tier 3, making the $35 cap applicable when the plan lists it.

Cost and Patient Assistance Programs for Montana Residents

Without insurance, a 5-pack of Tresiba FlexTouch pens (300 units each, 1,500 units total) retails for roughly $530 to $600 at Montana pharmacies. Several programs reduce this cost substantially.

Novo Nordisk My$99Insulin: Any patient, regardless of income, can purchase up to three vials or two packs of pens per month for $99 total through this program [13]. Enrollment is online and takes under 10 minutes.

NovoCare Patient Assistance Program: Uninsured or underinsured patients with household income at or below 400% of the federal poverty level may qualify for free Tresiba through NovoCare [13].

GoodRx and discount cards: GoodRx pricing at Billings-area pharmacies runs $480 to $510 for the 5-pen pack, roughly 10% below retail. This does not count toward insurance deductibles.

Montana HELP Act Medicaid: For patients who gained coverage through Montana's Medicaid expansion, Tresiba is not on the preferred drug list, but a formulary exception citing documented hypoglycemia on glargine carries a reasonable approval rate based on standard exception criteria [11].

Transferring an Existing Tresiba Prescription to Montana

Patients relocating to Montana can transfer an active Tresiba prescription from an out-of-state pharmacy to a Montana pharmacy for the remaining refills, provided the prescribing state's laws permitted the original prescription and Montana recognizes the prescriber's license. Insulin is not a controlled substance, so interstate transfer follows standard pharmacy transfer rules without DEA restrictions [9].

If the original prescriber is no longer licensed in Montana or the patient needs an updated prescription, a Montana-licensed telehealth provider can review records and issue a new prescription after a video visit. The ADA notes that continuity of basal insulin therapy should not be disrupted during transitions of care [6].

Mail-order pharmacies with nationwide reach can fill a Montana address with a prescription from any licensed U.S. prescriber, eliminating the transfer step entirely. Novo Nordisk's specialty pharmacy network ships Tresiba in temperature-controlled packaging with an ice-pack liner rated for 48-hour transit.

503A Compounding Pharmacies and Insulin Degludec in Montana

503A compounding pharmacies in Montana are licensed to compound patient-specific insulin preparations when a valid prescription exists [14]. However, insulin degludec is a biologic peptide produced through recombinant DNA technology, making true pharmaceutical-grade compounding practically unavailable. No 503A pharmacy can replicate Novo Nordisk's proprietary multi-hexamer assembly technology that produces degludec's ultra-long action.

The FDA's guidance on compounded insulin products notes that compounded insulin preparations "may not achieve the same pharmacokinetic profile as FDA-approved insulin products" [14]. A 503A Montana pharmacy can legally fill a written prescription for commercially manufactured Tresiba (dispensing, not compounding), but patients and providers should be clear that the product dispensed must be the FDA-approved Novo Nordisk product, not a compounded analog.

For patients seeking lower-cost alternatives, the FDA approved the first biosimilar to insulin glargine (Semglee, 2021) but no biosimilar to insulin degludec has received U.S. approval as of mid-2025 [15]. Patients needing degludec specifically must currently use the branded Tresiba product.

Titrating Tresiba After Your First Montana Prescription

The FDA-approved titration algorithm in the Tresiba label targets a fasting self-monitored blood glucose of 90 to 120 mg/dL (some clinicians use 80 to 110 mg/dL per ADA guidance) [4][6]. The standard approach:

• Starting dose: 10 units once daily for insulin-naive type 2 patients, or a 1:1 conversion from the prior basal insulin dose for patients already on basal therapy.
• Titration: Increase by 2 units every 3 days if fasting glucose remains above target on three consecutive mornings. Do not adjust more frequently than every 72 hours given the 42-hour duration of action.
• Hypoglycemia rule: If fasting glucose drops below 70 mg/dL, reduce the dose by 10% to 20% and recheck over 3 days before further increases.
• Ceiling: No maximum dose exists in the label, but doses above 1.0 units/kg/day in type 2 diabetes should prompt re-evaluation of total regimen.

A randomized titration study by Philis-Tsimikas et al. (N=302) published in Diabetes, Obesity and Metabolism found that a simple patient-driven 2-unit titration algorithm for degludec achieved target fasting glucose in 64% of patients at 26 weeks with a low rate of confirmed hypoglycemia (2.0 events/patient-year) [16]. Montana patients managing their own titration between telehealth check-ins can follow this protocol safely with proper education.

Storage and Administration Considerations for Montana's Climate

Montana winters routinely bring temperatures well below 0°F, and summers in the eastern plains can exceed 100°F. Both extremes damage insulin.

Unopened Tresiba pens and vials should be refrigerated at 36, 46°F (2, 8°C) until the expiration date [4]. An opened (in-use) pen may be stored unrefrigerated at room temperature below 86°F (30°C) for up to 56 days [4]. That 56-day window is longer than insulin glargine U-100's 28-day unrefrigerated limit and is clinically relevant for Montana patients doing outdoor work, hunting, or travel in remote areas.

Never freeze insulin degludec. Even brief freezing denatures the protein structure and renders the preparation ineffective without visible change in appearance [4]. Patients traveling in Montana winters should keep pens inside an insulating case in an inner jacket pocket, not in a vehicle glove box.

The CDC's diabetes management guidance recommends patients inspect insulin for cloudiness or particles before each injection; degludec is a clear, colorless solution and should never appear cloudy [17].

Monitoring After Starting Tresiba in Montana

After initiating Tresiba, the ADA recommends an A1C recheck at 3 months to assess dose adequacy, then every 3 months until at goal, and every 6 months once stable [6]. Continuous glucose monitoring (CGM) data, when available, provides a more granular picture: time-in-range (70 to 180 mg/dL) of >70% and time-below-range <4% are the consensus targets endorsed by the ADA and EASD [6].

Renal function should be rechecked annually or sooner if clinical status changes, given that declining eGFR increases hypoglycemia risk with all insulins [4]. A prospective cohort study in PLOS ONE (N=1,028 CKD patients on basal insulin) found that patients with eGFR <30 had a 2.3-fold higher rate of severe hypoglycemia compared to those with preserved renal function [18], underscoring the importance of dose reduction and closer monitoring.

Weight should be tracked at each follow-up visit. Insulin therapy is associated with modest weight gain (mean 1.5 to 2.0 kg at 26 weeks in DEVOTE) [2], and Montana telehealth follow-ups every 8 to 12 weeks allow timely adjustment.